DocGo Inc. (NASDAQ: DCGO) Investor Reminder: Schubert Jonckheer Investigating Possible False Claims, $4 Million in Stock Sales
DocGo (NASDAQ: DCGO) faces a significant legal investigation by Schubert Jonckheer & Kolbe LLP regarding alleged false statements and insider trading. A federal judge has allowed key claims in a securities fraud lawsuit to proceed, focusing on alleged misrepresentations about the former CEO's educational background and business operations.
The lawsuit claims that between April 2022 and September 2023, DocGo made misleading statements about the CEO's graduate degree and misrepresented relationships with UnitedHealthcare and Medicaid enrollment programs in New York. During this period, insiders sold approximately $4 million in company stock. The stock price dropped 25% after these revelations came to light in September 2023.
DocGo (NASDAQ: DCGO) è oggetto di un'importante indagine legale condotta da Schubert Jonckheer & Kolbe LLP per presunte dichiarazioni false e insider trading. Un giudice federale ha autorizzato il proseguimento di alcune accuse chiave in una causa per frode sui titoli, focalizzandosi su presunte falsificazioni riguardanti il background educativo dell'ex CEO e le operazioni aziendali.
La causa sostiene che tra aprile 2022 e settembre 2023, DocGo abbia rilasciato dichiarazioni fuorvianti sul titolo di studio del CEO e abbia travisato i rapporti con UnitedHealthcare e i programmi di iscrizione Medicaid a New York. In questo periodo, gli insider hanno venduto azioni per circa 4 milioni di dollari. Il prezzo delle azioni è crollato del 25% dopo che queste informazioni sono emerse a settembre 2023.
DocGo (NASDAQ: DCGO) enfrenta una importante investigación legal por parte de Schubert Jonckheer & Kolbe LLP debido a supuestas declaraciones falsas y uso de información privilegiada. Un juez federal permitió que continúen las principales acusaciones en una demanda por fraude de valores, centrada en supuestas tergiversaciones sobre la formación académica del ex CEO y las operaciones comerciales.
La demanda afirma que entre abril de 2022 y septiembre de 2023, DocGo emitió declaraciones engañosas sobre el título de posgrado del CEO y tergiversó las relaciones con UnitedHealthcare y los programas de inscripción de Medicaid en Nueva York. Durante este período, los insiders vendieron aproximadamente 4 millones de dólares en acciones de la empresa. El precio de las acciones cayó un 25% tras revelarse esta información en septiembre de 2023.
DocGo (NASDAQ: DCGO)는 Schubert Jonckheer & Kolbe LLP가 제기한 허위 진술 및 내부자 거래 혐의에 대한 중대한 법적 조사를 받고 있습니다. 연방 판사는 전 CEO의 학력과 사업 운영에 관한 허위 진술 혐의를 중심으로 한 증권 사기 소송의 주요 청구를 진행하도록 허가했습니다.
소송은 2022년 4월부터 2023년 9월까지 DocGo가 CEO의 대학원 학위에 대해 오해의 소지가 있는 진술을 했으며, 뉴욕의 UnitedHealthcare 및 Medicaid 등록 프로그램과의 관계를 잘못 전달했다고 주장합니다. 이 기간 동안 내부자들은 약 400만 달러 상당의 회사 주식을 매도했습니다. 이 사실이 2023년 9월 밝혀진 후 주가는 25% 하락했습니다.
DocGo (NASDAQ : DCGO) fait face à une importante enquête juridique menée par Schubert Jonckheer & Kolbe LLP concernant des déclarations mensongères présumées et des délits d'initiés. Un juge fédéral a autorisé la poursuite des principales allégations dans un procès pour fraude sur les valeurs mobilières, se concentrant sur des fausses déclarations présumées concernant le parcours éducatif de l'ancien PDG et les opérations commerciales.
Le procès affirme qu'entre avril 2022 et septembre 2023, DocGo a fait des déclarations trompeuses sur le diplôme de troisième cycle du PDG et a mal représenté les relations avec UnitedHealthcare et les programmes d'inscription Medicaid à New York. Pendant cette période, des initiés ont vendu environ 4 millions de dollars d'actions de la société. Le cours de l'action a chuté de 25% après la révélation de ces informations en septembre 2023.
DocGo (NASDAQ: DCGO) sieht sich einer bedeutenden rechtlichen Untersuchung durch Schubert Jonckheer & Kolbe LLP wegen angeblicher falscher Angaben und Insiderhandels gegenüber. Ein Bundesrichter hat wichtige Ansprüche in einer Klage wegen Wertpapierbetrugs zugelassen, die sich auf angebliche Falschdarstellungen bezüglich des Bildungshintergrunds des ehemaligen CEO und der Geschäftstätigkeiten konzentriert.
Die Klage behauptet, dass DocGo zwischen April 2022 und September 2023 irreführende Aussagen über den Hochschulabschluss des CEO gemacht und Beziehungen zu UnitedHealthcare sowie Medicaid-Anmeldeprogrammen in New York falsch dargestellt hat. In diesem Zeitraum verkauften Insider Aktien im Wert von etwa 4 Millionen US-Dollar. Der Aktienkurs fiel um 25%, nachdem diese Enthüllungen im September 2023 bekannt wurden.
- None.
- Federal judge ruled securities fraud lawsuit claims can proceed against DocGo
- Company allegedly made false statements about CEO's educational background and business operations
- Insiders sold $4 million in stock during the period of alleged misrepresentations
- Stock price fell 25% after revelations
- Alleged false claims about UnitedHealthcare contract and Medicaid enrollment programs
Insights
Judge allowing securities fraud claims against DocGo to proceed poses significant legal and financial risks to the company.
The advancement of key claims in a securities fraud lawsuit against DocGo represents a significant legal development with potential far-reaching consequences. Judge Katherine Polk Failla's ruling that allegations of "indisputably false" statements were made with fraudulent intent creates substantial legal exposure for the company. The lawsuit centers on three critical misrepresentations: falsely claiming the former CEO had a graduate degree, misrepresenting migrant enrollment in Medicaid programs, and fabricating a business relationship with
The timing of insider stock sales totaling approximately
The
On March 28, 2025, Judge Katherine Polk Failla of the
We are investigating potential wrongdoing by DocGo's directors and officers in connection with these allegations.
If you own stock in DocGo, you may have legal options. Visit https://www.classactionlawyers.com/docgo to learn more.
About Schubert Jonckheer & Kolbe LLP
Schubert Jonckheer & Kolbe represents consumers in class actions against corporate defendants, as well as shareholders in derivative actions against officers and directors. The firm is based in
Contact
Dustin L. Schubert
dschubert@schubertlawfirm.com
Tel: 415-788-4220
View original content:https://www.prnewswire.com/news-releases/docgo-inc-nasdaq-dcgo-investor-reminder-schubert-jonckheer-investigating-possible-false-claims-4-million-in-stock-sales-302520424.html
SOURCE Schubert Jonckheer & Kolbe LLP
FAQ
What are the main allegations in the DocGo (NASDAQ: DCGO) securities fraud lawsuit?
How much did DocGo (DCGO) stock drop after the allegations were revealed?
What is the value of insider stock sales during the period of alleged fraud at DocGo?
Who is investigating DocGo (DCGO) and what did the federal judge rule?
What is the time period covered by the DocGo securities fraud allegations?
